Contact
searchSearch
HMP Global
Login

News

News
Durvalumab Monotherapy Fails to Significantly Improve DFS in Intermediate-/High-Risk Renal Cell Carcinoma
05/30/2026
Stephanie Holland
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART...
05/30/2026
Oncology
News
Durvalumab Monotherapy Fails to Significantly Improve DFS in Intermediate-/High-Risk Renal Cell Carcinoma
05/30/2026
Stephanie Holland
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART...
05/30/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Cabozantinib Plus Nivolumab and Ipilimumab Maintains PFS Advantage in Clear Cell Renal Cell Carcinoma
02/26/2026
Stephanie Holland
Final results from the phase 3 COSMIC-313 trial demonstrate that cabozantinib plus nivolumab and ipilimumab continues to prolong progression-free survival in previously untreated patients with advanced clear cell renal cell carcinoma.
Final results from the phase 3 COSMIC-313 trial demonstrate that cabozantinib plus nivolumab and ipilimumab continues to prolong progression-free survival in previously untreated patients with advanced clear cell renal cell carcinoma.
Final results from the phase 3...
02/26/2026
Oncology
News
Selective Use of Stereotactic Ablative Radiotherapy Enables Durable Disease Control in Oligoprogressive Metastatic Renal Cell Carcinoma
02/06/2026
Stephanie Holland
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative...
02/06/2026
Oncology
News
Selective Use of Stereotactic Ablative Radiotherapy Enables Durable Disease Control in Oligoprogressive Metastatic Renal Cell Carcinoma
02/06/2026
Stephanie Holland
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative...
02/06/2026
Oncology
Lucian Zhao, MD
Videos
Stereotactic Ablative Radiotherapy Delays Systemic Therapy Escalation in Oligoprogressive Renal Cell Carcinoma
02/06/2026
Lucian Zhao, MD
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses...
02/06/2026
Oncology
Lucian Zhao, MD
Videos
Stereotactic Ablative Radiotherapy Delays Systemic Therapy Escalation in Oligoprogressive Renal Cell Carcinoma
02/06/2026
Lucian Zhao, MD
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses...
02/06/2026
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
Laurence Albiges, MD, PhD, Gustave Roussy
Videos
Addition of Cabozantinib to Nivolumab-Ipilimumab for Advanced Renal Cell Carcinoma in the First-Line Setting
03/13/2025
Laurence Albiges, MD, PhD
Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Laurence Albiges, MD, PhD,...
03/13/2025
Oncology

Recent News

News
New Conceptual Model Captures Patient Experience in Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study...
06/08/2026
Oncology
News
Real-World Analysis Identifies Challenges With Phlebotomy-Based Management of Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective...
06/08/2026
Oncology
News
Higher Starting Dose of Ropeginterferon Accelerates Responses in Patients With Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review...
06/08/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology
News
Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective...
06/08/2026
Oncology
News
Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/05/2026
Emily Estrada
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study...
06/05/2026
Oncology
News
Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia
06/05/2026
Emily Estrada
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study...
06/05/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use